Shuangcheng Company Profile
What is the competitive landscape for SHUANGCHENG
SHUANGCHENG has four approved drugs.
Summary for Shuangcheng
| US Patents: | 0 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 4 |
Drugs and US Patents for Shuangcheng
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shuangcheng | BIVALIRUDIN | bivalirudin | INJECTABLE;INTRAVENOUS | 210031-001 | Oct 23, 2019 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Shuangcheng | PACLITAXEL | paclitaxel | POWDER;INTRAVENOUS | 216355-001 | May 15, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Shuangcheng | BORTEZOMIB | bortezomib | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 216528-001 | Dec 17, 2025 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
